These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 16378990)

  • 1. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
    Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K
    J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
    J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells.
    Sun Y; Sijts AJ; Song M; Janek K; Nussbaum AK; Kral S; Schirle M; Stevanovic S; Paschen A; Schild H; Kloetzel PM; Schadendorf D
    Cancer Res; 2002 May; 62(10):2875-82. PubMed ID: 12019167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Processing of two latent membrane protein 1 MHC class I epitopes requires tripeptidyl peptidase II involvement.
    Diekmann J; Adamopoulou E; Beck O; Rauser G; Lurati S; Tenzer S; Einsele H; Rammensee HG; Schild H; Topp MS
    J Immunol; 2009 Aug; 183(3):1587-97. PubMed ID: 19587004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers.
    Benninger-Döring G; Pepperl S; Deml L; Modrow S; Wolf H; Jilg W
    Virology; 1999 Nov; 264(2):289-97. PubMed ID: 10562493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
    Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
    Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of the immunotherapeutic potential of a novel T cell epitope in the Epstein-Barr virus latent membrane protein 2.
    Lalonde A; Avila-Cariño J; Caruso M; de Campos-Lima PO
    Virology; 2007 May; 361(2):253-62. PubMed ID: 17207511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells.
    Sun H; Yao K; Chen Y; Zhou F
    Chin Med J (Engl); 2004 Oct; 117(10):1558-63. PubMed ID: 15498383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
    Turcanová V; Höllsberg P
    J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
    Gavioli R; Vertuani S; Masucci MG
    Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.
    Gileadi U; Moins-Teisserenc HT; Correa I; Booth BL; Dunbar PR; Sewell AK; Trowsdale J; Phillips RE; Cerundolo V
    J Immunol; 1999 Dec; 163(11):6045-52. PubMed ID: 10570292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
    Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation.
    Basler M; Lauer C; Moebius J; Weber R; Przybylski M; Kisselev AF; Tsu C; Groettrup M
    J Immunol; 2012 Aug; 189(4):1868-77. PubMed ID: 22772448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
    Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS
    Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.
    Micheletti F; Guerrini R; Formentin A; Canella A; Marastoni M; Bazzaro M; Tomatis R; Traniello S; Gavioli R
    Eur J Immunol; 1999 Aug; 29(8):2579-89. PubMed ID: 10458773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of locus-specific human lymphocyte antigen class I expression in Epstein-Barr virus-associated gastric cancer: implication for viral-induced immune evasion.
    Dutta N; Gupta A; Mazumder DN; Banerjee S
    Cancer; 2006 Apr; 106(8):1685-93. PubMed ID: 16541432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.